Dissemination (Meeting Coverage)

With limited data on the real-world treatment of follicular lymphoma in a contemporary cohort of patients, researchers examined treatment patterns and outcomes among nearly 2,400 adult patients with an initial follicular...

Immunotherapy (IO) + chemotherapy ± anti-angiogenics comprise FDA-approved 1L regimens for metastatic non-small cell lung cancer (NSCLC), with IO-only therapy approved only for PD-L1+ NSCLC. Patients with PD-L1 scores from...

Survival outcomes for patients with adenosquamous carcinoma of the lung are not well understood by virtue of reduced prevalence. To address this, a recent study sought to compare the long-term survival among patients with...

Testing for mutations in BRCA1 and BRCA2 is recommended for all women with ovarian cancer, given important implications for treatment and prognosis. Despite this recommendation, studies show that only a small percentage of...

Although ovarian cancer is the third most common Lynch syndrome (LS)-associated cancer in women, there is no established screening strategy to identify LS in this population. It is hypothesized that an adequate family history...

Disparities in the adherence to National Comprehensive Cancer Network (NCCN) guideline-directed treatment and socioeconomic characteristics may be responsible for the differences in ovarian cancer outcomes of ovarian cancer in...

The National Cancer Institute (NCI) Framework for patient-centered communication (PCC) in Cancer Care highlights the potential of PCC to improve health-related quality of life (HRQoL), but to date, few studies have empirically...

The ASCO Annual Meeting enters its second year in a virtual setting June 4-8, 2021, to ensure the safety and health of attendees while delivering groundbreaking science in oncology and timely information on clinical application...

Patients with advanced non-small cell lung cancer (NSCLC) experience fatigue and physical deconditioning, altering their quality of life (QoL). However, the safety and feasibility of high intensity exercise in advanced NSCLC has...

Prof. Tony Traboulsee talks to Physician’s Weekly about his study of tolebrutinib Presented at the American Academy of Neurology (AAN) 2021 Annual Meeting, Anthony Traboulsee, MD, professor and research chair of the MS Society...

Management of patients with multiple sclerosis (MS) in the era of disease modifying therapies (DMT) relies heavily on magnetic resonance imaging (MRI) and the support of dedicated multidisciplinary teams (MDTs). While decisions...

Cognitive impairment is a common and disabling feature of multiple sclerosis (MS), but a precise characterization of cognitive phenotypes in MS patients is still lacking. This study identified five cognitive phenotypes:...

Patients with MS may have difficulty performing double task (DT) while walking or causing interference. More research is needed in order to define the role of disability degree in the severity of the interference produced in the...